CureGene Achieves First Participant Dosed in U.S. Pivotal Trial for Evategrel (CG-0255), a Best-in-Class Antiplatelet Drug, Accelerating Global Commercialization
SHANGHAI, June 20, 2026 /PRNewswire/ -- CureGene Pharmaceutical today announced that the first participant has been successfully dosed in the...
Read moreDetails